HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D1 – AD brain scans – perfusion SPECT NUCLEAR MEDICINE.

Slides:

Advertisements

Similar presentations

Independent Research Presentation Vaibhav Garg, PD 1 “Happy is he who gets to know the reasons for things.” -- Virgil (70-19 BCE Roman Poet)

Advertisements

Slide 1 of 22 IAS–USA Victor G. Valcour, MD Professor of Geriatric Medicine University of California San Francisco Emerging Issues in HIV, Aging, and Cognition.

Decreased Nuclear Receptor Activity Mediates Downregulation of Drug Metabolizing Enzymes in Chronic Kidney Disease Through Epigenetic Modulation October.

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D2 – AD brain scans – metabolism - PET NUCLEAR MEDICINE.

Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.

Alzheimer’s Disease Edwin Onattu P. 3.

Careers in Professional Geropsychology Professional Geropsychology Synarchy: A co-ordinating group of organizations in psychology and aging January 2013.

TESTING A LEPTIN PRODUCT AS A NOVEL THERAPY FOR ALZHEIMER’S DISEASE

MemTrax (Computerized Memory Screen) American Association of Geriatric Psychiatry (AAGP) March 2, 2007 J. Wesson Ashford, M.D., Ph.D. Stanford / VA Aging.

Screening for Alzheimer’s disease Herman Buschke, MD Einstein Aging Study (NIA AG-03949) Department of Neurology Albert Einstein College of Medicine.

Office of Public Health Ansgar Furst, Ph.D. Director of Neuroimaging Laboratory, WRIISC VA Palo Alto, CA Clinical Assistant Professor (Affiliated) of Psychiatry.

Communicating with Dementia Patients of Different Severity Levels

Edward Kaye 1,2, Kie Honjo 3,4, Ana Petrovic-Poljak 5, Robert van Reekum 6, David Streiner 1,6,7,8,9, Alan Wilson 6,10, Sandra Black 3,4,11, Morris Freedman.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND.

The social institution responsible for the maintenance of health and the advancement of the practice and use of medicine.

Risk of Developing Alzheimer’s Disease in Persons with MCI

ALZHEIMER’S PART 2. AD VIDEO

ALZHEIMER’S DISEASE BY JOSEPH MOLLUSO.

ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California Calabasas, California.

Copyright © 2007, 2003 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 37 Confusion and Dementia.

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

Alzheimer’s Society, UK Our research programme

Slide 1 of 25 From VG Valcour, MD, at Washington, DC: June 18, 2013, IAS-USA. IAS–USA Victor G. Valcour, MD Professor of Geriatric Medicine University.

ALZHEIMER PATHOLOGY AND NEUROPLASTICITY AD ATTACKS NEUROPLASTIC MECHANISMS NEUROPLASTICITY AS THE FOCUS OF THE ALZHEMIER ATTACK ALZHEIMER ATTACK AS A MODEL.

Aetiology of Psychiatric Disorders Dr. Fatima Alhaidar Professor & Consultant Child & Adolescent Psychiatrist College of Medicine, KSU.

Introduction Alzheimer’s is a disease that affects the brain. About 4 million people in the United States have it. It is predicted that 1 in 85 people.

Delusions, behavioural symptoms, quality of life and caregiver effects in AD Delusions, behavioural symptoms, quality of life and caregiver effects in.

Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.

Statistical Issues for Developing Alzheimer Screening Tests J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California.

Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.

1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.

Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology Alzheimer’s Disease Avi Gandhi (2009)

Rules of the Road by Joan Bauer. Here are pictures of human brain. The brain on the upper left is a healthy human brain. The brain on the upper right.

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

Detecting Individual Differences in Changes in Memory Functioning Dr. Len Lecci Professor of Psychology University of North Carolina Wilmington Director.

Mental Health Insurance, Parity & Public Policy Richard Scheffler, Ph.D., Distinguished Professor of Health Economics and Public Policy at UC Berkeley.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part C – AD brain scans - anatomical NUCLEAR MEDICINE GRAND.

Cleveland Clinic Science Internship Program Communicating with Dementia Patients of Different Severity Levels Michael Ciulla, Kurt Karis, CTRS, Tria O’Maille,

Epidemiological and Pharmacoeconomic Aspects of Alzheimer‘s Disease and Dementia.

National Institute on Aging

Psychosis in Dementia Conclusions Psychosis in dementia is distressful and disturbing to patients and  Is similar across the spectrum of the dementia.

Body Text Add description of study, duration, compensation, or any other information necessary to explain the study and the responsibilities of the participants.

Canadian Study of Health and Aging The Prevalence of Dementia 1991 Baseline Study.

Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.

Psychologist: a scientist who studies the mind and behavior of humans and animals.

The Facts about Alzheimer’s Disease By: Mr. Frantz.

Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.

PHQ-9 Severity and Screening Tests Predictive of Remission Outcomes at Six Months Kurt B. Angstman, MS MD Associate Professor John M. Wilkinson Assistant.

The Facts about Dementia and Other Related Conditions Developed by the: University of Wisconsin Oshkosh and Wisconsin Department of Health Services.

ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California October, 2004 Slides.

Comparison of Risk Factors for Early-Onset versus Late-Onset Alzheimer Disease OBJECTIVE To compare early-onset (before 65) Alzheimer disease (AD) patients.

CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS

ABSTRACT Figure 3. Results from two ANOVAs (HV > 0, MDD > 0) and a flexible factorial design (HV vs. MDD) in the unpleasant > neutral contrast are shown.

Dr Christa Beesley Accountable Officer Brighton and Hove Clinical Commissioning Group #dementiaconference.

Aka STEEL VALLEY SENIORS SURVEY (SVSS)

Substance Use Disorders in People Living with HIV

Cognitive Disorders and Aging

Early Cognitive Decline and the Aging Brain - Overview

چون آن مرغی که درهر برگ گل نقش خزان بیند

بسم الله الرحمن الرحیم.

Health Services Research Postdoctoral Fellowship

Adam P. Spira, Ph.D. Associate Professor, Department of Mental Health

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

Manjula Kurella Tamura, Kristine Yaffe Kidney International

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

CT perfusion maps of MTT

Background of PI Name: Wen-Yih Isaac Tseng, MD, PhD

ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;

Presentation transcript:

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D1 – AD brain scans – perfusion SPECT NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences Senior Research Scientist, Stanford / VA Aging Clinical Research Stanford University and VA Palo Alto Health Care System January 5, 2010 Slides at: (Dr. Ashford’s lectures)

Relation of SPECT severity to duration of dementia (years) Shih, Ashford et al., 2000 SPECT severitySPECT gradeDementia Duration Normal0start= 0 years Near-Normal11 Mild22 Mild-moderate33 Moderate44 Moderate-severe55 Severe66 Severe-profound77 Profound88

SPECT scans – normalization to cerebellum on Left to Right, to Talraich space

Ashford et al, 2000 SPECT scan locations of cortex, local elements shown with Brodman areas, colored according to correlation with estimation of dementia severity (derived from the Mini-Mental State Exam)